Non-Smad TGF-β signaling pathways have been increasingly recognized as important components of TGF-β signaling, alongside the well-established Smad pathways. These non-Smad pathways contribute to TGF-β signaling through three main mechanisms: (1) directly modifying Smad function by phosphorylation or other modifications; (2) modulating the activity of other signaling proteins that are directly influenced by Smads; and (3) interacting with or being phosphorylated by TGF-β receptors, thereby initiating parallel signaling that cooperates with Smad pathways. These non-Smad pathways provide quantitative regulation of the signaling pathway and serve as nodes for crosstalk with other major signaling pathways, such as tyrosine kinase, G-protein-coupled, or cytokine receptor pathways. TGF-β signaling is mediated through receptor serine/threonine kinases and intracellular Smad proteins. In addition, several intracellular proteins that mediate signaling by receptor tyrosine kinases, G-protein-coupled receptors, or cytokine receptors also participate in the TGF-β signaling network. The Smad pathway is an evolutionarily conserved signaling module that transmits signals to the nucleus and is crucial for the precise execution of tissue- and organ-patterning programs during animal development. However, the relative importance and evolutionary or developmental significance of non-Smad effectors have been less clear. Recent evidence suggests that these effectors play important roles downstream of TGF-β ligands. Non-Smad signaling proteins downstream of TGF-β superfamily receptors include pathways that directly modify Smad function, pathways that are modulated by Smads and transmit signals to other kinases, and pathways that are directly activated by TGF-β receptors. These pathways are involved in various physiological responses, including apoptosis, epithelial-mesenchymal transition (EMT), cell proliferation, and matrix regulation. For example, TGF-β induces apoptosis through the activation of MAPKs such as p38 and JNK, and through the activation of non-Smad proteins like TAK1. TGF-β also promotes EMT by activating Rho GTPases and other signaling pathways, and by modulating the expression of genes involved in EMT. In addition, TGF-β signaling is involved in cell proliferation and differentiation. TGF-β inhibits the growth of non-transformed epithelial, endothelial, and hematopoietic cells, and primary fibroblasts of embryonic origin. It can also promote cell proliferation in certain transformed cells and immortalized fibroblasts. TGF-β signaling is involved in the regulation of gene expression, including the expression of genes that regulate the cell cycle, such as p21, p15, and p57. TGF-β also regulates the expression of genes involved in matrix regulation, such as plasminogen activator inhibitor 1 (PAI-Non-Smad TGF-β signaling pathways have been increasingly recognized as important components of TGF-β signaling, alongside the well-established Smad pathways. These non-Smad pathways contribute to TGF-β signaling through three main mechanisms: (1) directly modifying Smad function by phosphorylation or other modifications; (2) modulating the activity of other signaling proteins that are directly influenced by Smads; and (3) interacting with or being phosphorylated by TGF-β receptors, thereby initiating parallel signaling that cooperates with Smad pathways. These non-Smad pathways provide quantitative regulation of the signaling pathway and serve as nodes for crosstalk with other major signaling pathways, such as tyrosine kinase, G-protein-coupled, or cytokine receptor pathways. TGF-β signaling is mediated through receptor serine/threonine kinases and intracellular Smad proteins. In addition, several intracellular proteins that mediate signaling by receptor tyrosine kinases, G-protein-coupled receptors, or cytokine receptors also participate in the TGF-β signaling network. The Smad pathway is an evolutionarily conserved signaling module that transmits signals to the nucleus and is crucial for the precise execution of tissue- and organ-patterning programs during animal development. However, the relative importance and evolutionary or developmental significance of non-Smad effectors have been less clear. Recent evidence suggests that these effectors play important roles downstream of TGF-β ligands. Non-Smad signaling proteins downstream of TGF-β superfamily receptors include pathways that directly modify Smad function, pathways that are modulated by Smads and transmit signals to other kinases, and pathways that are directly activated by TGF-β receptors. These pathways are involved in various physiological responses, including apoptosis, epithelial-mesenchymal transition (EMT), cell proliferation, and matrix regulation. For example, TGF-β induces apoptosis through the activation of MAPKs such as p38 and JNK, and through the activation of non-Smad proteins like TAK1. TGF-β also promotes EMT by activating Rho GTPases and other signaling pathways, and by modulating the expression of genes involved in EMT. In addition, TGF-β signaling is involved in cell proliferation and differentiation. TGF-β inhibits the growth of non-transformed epithelial, endothelial, and hematopoietic cells, and primary fibroblasts of embryonic origin. It can also promote cell proliferation in certain transformed cells and immortalized fibroblasts. TGF-β signaling is involved in the regulation of gene expression, including the expression of genes that regulate the cell cycle, such as p21, p15, and p57. TGF-β also regulates the expression of genes involved in matrix regulation, such as plasminogen activator inhibitor 1 (PAI-